CPAP Was Tested as a Recovery Tool in Healthy Endurance Runners
A Brazilian trial examined whether nocturnal CPAP could improve recovery in healthy male endurance runners who did not have obstructive sleep apnea. The question was not whether these athletes needed treatment for a sleep disorder; it was whether a positive airway pressure device, applied during sleep, could change the physiology of recovery after demanding training blocks. In practice, that means the study treated CPAP less as a respiratory therapy and more as a controlled stress-modifying tool layered onto elite training.
The protocol focused on a narrow but clinically interesting population: men aged 20 to 45 years who had been runners for at least one year, had no respiratory problems, and were free of sleep apnea. Twelve participants completed the study. Their training was organized into two distinct workloads, first a high-intensity, high-volume block and then a low-intensity, low-volume block, with sleep and recovery assessed across both phases.
The sequence matters because the intervention was not randomized. Every participant first completed the training periods without nocturnal CPAP and then repeated the corresponding periods with CPAP during sleep. That fixed order creates a straightforward within-person comparison, but it also leaves room for time effects, adaptation to training, and other changes that can unfold naturally across repeated exercise cycles.
Sleep Physiology Sat at the Center of the Design
Investigators measured REM sleep latency as the primary outcome, using overnight polysomnography at baseline and after each five-day training period. The choice is biologically sensible. Training stress does not only affect muscles and metabolism; it also reshapes the architecture of sleep, and REM timing can reflect how the nervous system is responding to accumulated load, arousal, and overnight recovery demands.
Sleep assessment went far beyond a single endpoint. The protocol also included sleep onset latency, total sleep time, wake after sleep onset, respiratory disturbance index, apnea-hypopnea index, and awakening index. In other words, the trial was built to capture whether CPAP altered both sleep continuity and breathing stability, even in athletes who were not diagnosed with sleep-disordered breathing.
That is an unusual premise, but not an illogical one. Endurance athletes often live in a narrow physiologic margin, where small changes in sleep quality, nocturnal arousals, and autonomic strain can alter the next day’s training tolerance. If CPAP reduced subtle upper-airway instability or smoothed nocturnal breathing patterns, it could plausibly lower sleep fragmentation and shift downstream recovery markers, even in a non-apneic population.
Biomarkers Were Chosen to Track Muscle Stress and Anabolic Recovery
Blood sampling added a second layer of interpretation. The study measured serum aldolase, hematocrit, leukocyte count, insulin-like growth factor 1, insulin, uric acid, lactate dehydrogenase, and total testosterone after each training period. These markers cover several biologic domains at once: muscle injury, hemoconcentration, immune activation, endocrine signaling, and metabolic stress.
The logic here is clinical as much as athletic. A high-volume training cycle can elevate muscle enzymes, alter inflammatory and hematologic parameters, and change the hormonal environment that supports repair. If nocturnal CPAP improved recovery, the effect might appear not only in sleep architecture but also in biomarkers that reflect tissue breakdown and the body’s attempt to rebuild after repeated exertion.
Psychological and recovery-related questionnaires were included as well, expanding the trial beyond laboratory measures. Actigraphy, sleep diaries, and heart rate monitoring helped anchor the overnight data to day-to-day training behavior and physiologic response. The resulting design linked subjective experience, objective sleep metrics, and biochemical readouts into one tightly staged experimental schedule.
A Fixed-Sequence Design Framed the Entire Experiment
The study used a single-group, fixed-sequence design. Participants completed the non-CPAP conditions first and the CPAP conditions afterward. No randomization, masking, or parallel-group assignment was used.
That setup makes the experiment easy to follow and easy to execute in a small cohort, but it also narrows what can be concluded. The comparison is intra-individual rather than between independent groups, so any observed differences would have to be interpreted in the context of repeated exposure to training, rest, and testing. The two-day rest periods placed between the high- and low-intensity blocks may have helped separate the phases, yet they do not erase the possibility that recovery dynamics changed because the athletes had already been through the first cycle.
The athletes underwent a fairly intensive screening process before enrollment. Baseline assessments included polysomnography, otorhinolaryngologic evaluation, electrocardiography, blood tests, cardiopulmonary exercise testing, and questionnaires. That screening was important because the trial aimed to isolate the effect of CPAP in a healthy athletic cohort, not to treat underlying airway pathology or cardiopulmonary disease.
What the Study Can and Cannot Tell Clinicians
The completed trial enrolled 12 men in São Paulo, Brazil, and ran from January 2012 through July 2015, with the last update posted in October 2026. The study record does not post results, so no efficacy or safety signal can be claimed from the available registry entry. What remains is the framework: a precise, physiologically ambitious experiment designed to ask whether an intervention usually reserved for sleep-disordered breathing could influence recovery in high-performance runners without apnea.
The clinical interest is easy to see. Sleep is one of the few recovery systems that can be manipulated without changing the training session itself, and CPAP has a strong mechanistic profile for stabilizing airway patency and reducing sleep fragmentation. In an athlete with repeated exposure to high workload, even modest improvement in overnight sleep continuity could matter if it translated into better endocrine balance, reduced perceived fatigue, or more favorable biomarker patterns.
At the same time, this was a small, male-only study built around a narrow athletic phenotype. The absence of published results in the registry record means the practical effect of CPAP in this setting remains unresolved. For now, the trial stands as a carefully structured physiologic probe rather than a basis for routine athletic practice, and its value lies in the specific sleep, blood, and recovery measures it chose to track across fixed training loads.